If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

Related content
Volume 1, Number 1, May 2001

all issues | next issue >

Book Reviews

Favourites:Add to Favourites

pp. i-i(1)
Author: Buolamwini, J.K.


Favourites:Add to Favourites

Challenges of Cancer Drug Design A Drug Metabolism Perspective
pp. 1-32(32)
Authors: Sanchez, R.I.; Mesia-Vela, S.; Kauffman, F.C.

Favourites:Add to Favourites

The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
pp. 49-57(9)
Authors: ODwyer, M.E.; Druker, B.J.

Favourites:Add to Favourites

Structure-Based Design of Novel Anticancer Agents
pp. 59-71(13)
Authors: Uckun, F.M.; Sudbeck, E.A.; Mao, C.; Ghosh, S.; Liu, X.; Vassilev, A.O.; Navara, C.S.; Narla, R.K.

Favourites:Add to Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more